Must Read

Drug startups coalesce around condensates

Authors Elie Dolgin
Details Elie Dolgin; Nat Biotechnol; 2021;
Published February 9, 2021
DOI 10.1038/s41587-021-00828-4
Source View on PubMed

Three startups debuted in late 2020, all aiming to treat disease by manipulating the physiochemical and regulatory processes in cells that drive membraneless hubs associated with disease pathogenesis. The field’s frontrunner, Dewpoint Therapeutics, also signed a major research pact last month with Pfizer — Dewpoint’s third such deal with a large pharma partner since the company’s inception two years ago…

Join the conversation

Create an Account or Sign In to comment.